Epstein-Barr Virus Binding to CD21 Activates the Initial Viral Promoter via NF-κB Induction

By Naozuki Sugano, Weiping Chen, M. Luisa Roberts, and Neil R. Cooper

Summary

Epstein-Barr virus (EBV), an oncogenic human herpesvirus, binds to and infects normal human B lymphocytes via CD21, the CR2 complement receptor. Studies of the mechanisms that enable EBV to infect nonactivated, noncycling B cells provide compelling evidence for a sequence of events in which EBV binding to CD21 on purified resting human B cells rapidly activates the NF-κB transcription factor, which, in turn, binds to and mediates transcriptional activation of Wp, the initial viral latent gene promoter. Thus, EBV binding to its cellular receptor on resting B cells triggers an NF-κB-dependent intracellular signaling pathway which is required for infection.

I nfection of normal human B lymphocytes by EBV, a ubiquitous transforming human herpesvirus with oncogenic potential, is initiated by binding of the virus to CD21 (CR2, complement receptor type 2), the receptor for C3dg, the terminal activation/processing fragment of the third complement component (1, 2). EBV binds to CD21 via a short primary sequence epitope in the major viral envelope glycoprotein (gp350/220), which is homologous in sequence to the binding epitope in C3dg (3). CD21 is a member of an intracellular signaling pathway which modulates B cell activation, growth, and differentiation (1, 2). Unlike most viruses, EBV infects nonactivated, resting cells. In the present study, we evaluated the hypothesis that an intracellular signaling pathway initiated by EBV binding to CD21 enables EBV to infect resting B cells.

Prominent among the signaling pathways that rapidly convert extracellular signals into changes in gene expression is the NF-κB family of transcription factors. NF-κB, which is rapidly activated by a variety of extracellular ligands, modulates the transcriptional activation of numerous genes bearing NF-κB binding sites in their promoters, including genes involved in cellular growth, differentiation, and immune regulation (4). Members of the NF-κB family regulate the expression of several viral genes and, conversely, a number of viral proteins mediate their effects via NF-κB activation. NF-κB, first described as a B cell-specific transcription factor that binds to the immunoglobulin kappa light chain enhancer (5), is an inactive cytoplasmic homodimeric or dimeric complex of two NF-κB family members in noncovalent association with a member of the IκB family of inhibitory proteins in most cells. NF-κB-activating stimuli trigger IκB release from NF-κB, thereby unmasking the NF-κB localization signal and enabling the activated transcription factor to enter the nucleus and bind to specific NF-κB motifs in target genes; such rapid NF-κB activation is independent of new protein synthesis.

Materials and Methods

Assessment of NF-κB Activation. Nonactivated (resting) small B cells purified from human tonsils (6) were incubated at 37°C with one of the following: B95-8 or Akata strain EBV (references 7, 8; 3 × 10^6 cells, ~10^9 virions/cell), 100 nm microbeads coated with either purified C3dg or BSA (references 6, 9; 6 μg of protein on ~8 × 10^11 beads), soluble OKB7 (Ortho Diagnostic Systems, Raritan, NJ) mAb to CD21 (12 μg/3 × 10^6 cells), or the gp105 receptor binding fragment of gp350/220 (10) in soluble form (6 μg/3 × 10^6 cell). In some studies, the same amounts of soluble OKB7 or gp105 were preincubated with the B cells before EBV addition. In other experiments, purified B cells were incubated in plastic 6-well tissue culture plates precoated with BSA (50 ng/well) or gp105 (50 ng/well) (3 × 10^6 cells/well; reference 11). Nuclear extracts were prepared and 3 μg were incubated with a [32P] end-labeled NF-κB consensus probe (GGGACTTTCC), a mutant NF-κB probe (GGGACTTTCC) (Promega Corp., Madison, WI; reference 12), the Wp NF-κB-like sequence (GGGGGACCA), or a mutant Wp sequence (GCGGGGACCA). Competition studies used a 50-fold excess of the appropriate unlabeled oligonucleotides. In some studies, the B cells were incubated with calphostin C (50 nM; Calbiochem Corp., La Jolla, CA), aspirin (1 or 5 mM), or N-acetylcysteine (20 mM) for 2 h before the addition of EBV.

Electrophoretic Mobility Shift Assay (EMSA). Electrophoretic mobility shift assays (EMSA) were performed as described (12). In supershift EMSAs, nuclear extracts were incubated for 60 min with 2 μg of polyclonal Abs to NF-κB subunits (Santa Cruz Biotechnology, Santa Cruz, CA) before addition of the labeled probes (12).

Western Blotting Studies. Western blots were probed with a polyclonal Ab to IκB (Santa Cruz Biotechnology) to assess IκB degradation.
CD21 Signaling Activates the Initial EBV Promoter

RNase Protection Studies. These were carried out with RNA from 10^6 live cells (Ficoll-Paque; Pharmacia Biotech, Piscataway, NJ) 24 h after EBV addition with antisense probes for Epstein-Barr virus nuclear antigen (EBNA) 2 and the ribosomal protein L32 (rpL32) housekeeping gene, as described (11).

EBV-induced B Cell Transformation. Inclusion of 3H-thymidine was assessed as described (11).

Reverse Transcriptase PCR to Evaluate Activation. RNA was extracted (Tripure; Boehringer Mannheim, Indianapolis, IN), reverse transcribed with Moloney murine leukemia virus reverse transcriptase (GIBCO BRL, Gaithersburg, MD), 20% of the product (from 10^6 cells) was analyzed by PCR (45 cycles with replenishment of dNTP and Taq at 30 cycles) with the following primers: 5'-GTCCACACAAATCCTAG-3' and 3'-CCCTGAAAGTGACCCGCTTA-5', which yield a 210-bp product.

Transfection Studies and Chloramphenicol Acetyltransferase Assays. Transfections in 293 cells used the lipofectamine procedure, using 1 μg of each plasmid and vector (pSV2gpt and pSG5) to balance the amount of DNA (12). Chloramphenicol acetyltransferase (CAT) assays were carried out with a CAT enzyme

**Figure 1.** NF-κB induction by CD21 ligands. (A) NF-κB activation by EBV. Nuclear extracts from purified resting B cells incubated with B95-8 EBV for the designated times were analyzed by EMISA for ability to bind to an NF-κB consensus probe. (B) Specificity of NF-κB binding. Homologous wild type (wt) and mutant (mut) NF-κB probes were evaluated for ability to inhibit binding of the NF-κB consensus probe by EMSA. (C) NF-κB activation by C3dg. Nuclear extracts from purified resting B cells incubated with microbeads coated with C3dg or BSA were evaluated for the presence of activated NF-κB by EMSA. (D) CD21 dependence of NF-κB activation. Purified resting B cells were incubated with soluble gp105 or OKB7 for 1 h, or with the same amounts of gp105 (EBV + gp105) or OKB7 (EBV + OKB7) for 1 h before EBV addition. Nuclear extracts were prepared 15 min after EBV addition. B cells were also incubated in BSA- or gp105-coated plastic culture wells (pl.) for 15 min. Ability to bind to an NF-κB consensus probe was evaluated by EMSA. (E) Composition of NF-κB. Nuclear extracts from purified resting B cells 30 min after EBV addition were incubated with p50, p65, c-rel or p52 Abs to NF-κB subunits before addition of the NF-κB consensus probe and analysis by EMSA. (F, top) Effect of calphostin C on NF-κB activation. Nuclear extracts prepared 30 min after EBV addition to purified resting B cells that had been preincubated for 2 h with calphostin C (50 nM) or buffer, were examined for NF-κB activation by EMSA. (F, bottom) Assessment of IκBa. The same samples were evaluated for IκBa by the Western blotting procedure. Control lanes (−) do not contain EBV.

Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; EBNA, Epstein-Barr virus nuclear antigen; EMSA, electrophoretic mobility shift assay; LTR, long-terminal repeat; PKC, protein kinase C; rpL32, ribosomal protein L32; RT, reverse transcriptase.
Results and Discussion

Nuclear extracts prepared from highly purified resting (nonactivated) human tonsil B cells incubated with EBV for varying periods of time at 37°C were assessed for ability to bind to an NF-κB consensus probe in gel shift assays. Nuclear NF-κB–binding activity increased rapidly from low constitutive levels to reach peak values 15–30 min after EBV addition (Fig. 1 A). Activation was inhibited by the unlabeled wild-type oligonucleotide, but not by a mutant oligonucleotide, demonstrating specificity (Fig. 1 B). After a modest decline, EBV-induced NF-κB–binding activity increased 24 h after EBV addition, likely due to the actions of EBNA 2 and latent membrane protein 1, two EBV latent genes expressed in the first days after infection (13, 14) which activate NF-κB (15, 16). Similar studies with purified tonsil B cells from >10 individuals with two EBV strains (Akata and B95-8) gave comparable results. C3dg-coated microbeads gave the same pattern of rapid NF-κB activation (Fig. 1 C) but without the second increase 24 h later.

Additional studies were performed to confirm the dependence of NF-κB activation on CD21 ligation. Among these were experiments to assess the ability of the recombinant soluble gp105 fragment of EBV gp350/220 and mAb OKB7 to inhibit EBV-induced NF-κB activation; both of these proteins bind to CD21 and block EBV binding to, and infection of, B cells (3, 10, 17–19). The EBV-induced 15-fold increase in NF-κB binding activity was reduced to 4- and 2.5-fold by preincubating the cells with soluble gp105 and OKB7, respectively, before EBV addition (Fig. 1 D); these values are close to the 2- and 3-fold NF-κB induction produced by gp105 and OKB7 alone, respectively (Fig. 1 D). In another approach, gp105 adsorbed to plastic increased NF-κB–binding activity ~12-fold over control levels obtained with BSA-coated wells (Fig. 1 D), a finding which also suggests that CD21 aggregation is important for NF-κB induction. The demonstration that C3dg, gp105, and OKB7 all activate NF-κB provides unequivocal direct evidence that CD21 ligation alone mediates activation of the transcription factor. Furthermore, EBV-induced NF-κB activation is solely dependent on CD21 ligation, and is not due to other virus-cell interactions, since both gp105 and OKB7 inhibit the marked NF-κB activation induced by EBV.

Supershift EM SASs carried out to determine the composition of EBV-induced NF-κB showed that Abs to p50, as well as p65, produced prominent supershifted bands, whereas Abs to p52 and c-rel gave very weak supershifted bands (Fig. 1 E). Thus, activated NF-κB induced by EBV binding to CD21 contains both p50 and p65, but possible contributions of p52 and c-rel cannot be eliminated.

NF-κB activation is mediated by a process which involves IκB phosphorylation on specific serine residues, ubiquination, and degradation (20). The signaling pathway and enzyme(s) responsible for phosphorylating IκB in cells have not been definitively identified, although protein kinase C (PKC) and several other kinases possess this property in vitro (21). In the present studies, EBV-induced NF-κB activation was associated with IκB degradation (Fig. 1 F). NF-κB activation and IκB degradation were both markedly inhibited by preincubating purified resting B cells with 50 nM calphostin C, a potent (IC₅₀ = 50 nM), specific PKC inhibitor in the nM concentration range for 2 h before EBV addition (22, 23; Fig. 1 F). These findings strongly imply that NF-κB activation triggered by EBV binding to CD21 on B cells is PKC dependent, and associated with IκB degradation.

The biological relevance of EBV-induced NF-κB activation was addressed by evaluating the effects of aspirin on the initial stages of EBV infection; aspirin inhibits NF-κB activation induced by different stimuli in multiple cell types.
EBV-induced NF-κB activation was markedly inhibited by pretreating resting B cells for 2 h with 5 mM or 1 mM aspirin (Fig. 2A). R N ase protection assays showed that aspirin inhibited transcription of E B N A 2 , one of the first expressed EBV latent genes (Fig. 2B). Aspirin, which is not a general transcriptional inhibitor, only modestly reduced messenger RNA levels of the rpL32 housekeeping gene (50% at 5 mM; Fig. 2B). Scanning and expression of the pixel density units as E B N A 2 /rpL32 ratios to compensate for the effects on rpL32 transcription revealed that 0.5, 1, and 5 mM aspirin inhibited E B N A 2 transcription by 12, 58, and 73%, respectively. Pretreatment with 1 or 5 mM aspirin also inhibited EBV-induced thymidine incorporation 14 d after infection by 99%; this time point largely aspirin also inhibited transcription of E B N A 2, one of the first stages of EBV infection of resting B cells.

Since aspirin inhibited E B N A 2 transcription, we focused on the initial E B N A 2 promoter, W p, as a potential target for the N F-κB–dependent signaling pathway. E B N A 2 and E B N A leader protein are initially transcribed from W p, a promoter located in the major long internal repeat (BamH1 W; reference 27). Transcription from W p does not require new protein synthesis (28). For W p to represent a target of the signaling pathway, the viral genome must have reached the nucleus and transcriptional activation of W p must have occurred within the time frame of EBV-induced N F-κB activation. Although viral nucleocapsids are detectable near the nucleus 60 to 90 min after infection (29), E B N A 2 RNA and protein have not been detected until 8–12 h after EBV addition (13, 14). In the present studies, transcription from W p was evident 3 h after EBV addition to resting B cells by R T P C R (Fig. 3A), clearly within the time of marked N F-κB activation; in addition, W p activation was sensitive to 50 nM calphostin C (Fig. 3B), further implicating the N F-κB signaling pathway. The earlier time frame for viral gene transcription obtained here in comparison to previous studies is undoubtedly explained by the use of the more sensitive R T P C R technique.

In examining the region in W p‘ to the T A T A box, an N F-κB–like sequence was found (G G G G A C C A C versus G G G G A / G N N C /T C / T C C for the N F-κB consensus binding sequence) beginning 19 nucleotides 5′ to the T A T A box. Adenine, rather than cytosine, at position 9 has been reported to be occasionally used in N F-κB–binding sequences in other promoters (30). E M S A s revealed that nuclear extracts from resting B cells 30 min after EBV addition bound to an oligonucleotide that duplicated the W p N F-κB–like sequence (Fig. 4A). Binding was inhibited by an oligonucleotide with the same sequence and by a probe duplicating the N F-κB–binding site, but unaffected by a mutant W p oligonucleotide (Fig. 4A). Reciprocally, binding of the consensus N F-κB probe was competed by the W p probe and the N F-κB consensus probe, but not by the mutant W p probe (Fig. 4A).

The final series of studies were carried out to determine whether EBV binding to C D 2 1 activates W p transcription via N F-κB. It was not possible to transfect resting human B cells with a W p reporter construct and then add a C D 2 1 ligand to directly answer this question because of the known extremely low efficiency with which resting B cells support the expression of transfected D N A (12, 31). T r ansfection efficiency is modestly improved by pretreatment of the cells with a phorbol ester (31), but this results in N F-κB activation (not shown). Although transfection efficiency is also improved by preexposing B cells to the major EBV glycoprotein (12, 32), this approach was not feasible here since the viral protein is a C D 2 1 ligand. As an alternative approach, human 293 primary embryonal kidney cells were cotransfected with p50, p65, or p50 plus p65 expression plasmids together with one of two C A T reporter plasmids.
NF-κB activated by EBV binding binds to and activates Wp. (A) Binding of activated NF-κB to the NF-κB–like site in Wp. Nuclear extracts from purified resting B cells 30 min after addition of EBV were evaluated for ability to bind to labeled probes duplicating the NF-κB–like site in Wp (left), or an NF-κB consensus sequence (right), by EMSA. Competition studies were carried out with unlabeled probes reflecting the wild-type Wp sequence (Wp wt), Wp bearing a mutant NF-κB–like sequence (Wp mut), or the wild-type NF-κB consensus sequence (NF-κB). (B) Transcriptional activation of Wp by NF-κB. CAT activity assays were carried out in human 293 cells cotransfected with p50, p65, or p50 plus p65 expression plasmids together with a Wp CAT reporter plasmid, a Wp CAT reporter plasmid with a mutated NF-κB site, or an HIV CAT reporter plasmid.

![Figure 4](image-url)

We thank W. Haseltine, A. Israël, N. Mackman, C. Rooney, C. Rosen, and J. Sodroski for plasmids; G. Verduzco for technical assistance; G. Nemerow for recombinant gp105; B. Bradt for purified C3dg; and
R eferences

1. Nemerow, G.R., A.T. Luxembourg, and N.R. Cooper. 1994. C.D.21/CR2: its role in EBV infection and immune function. Epstein Barr Virus (Virol. 63:1531-1539.
2. Scala, G., I. Quinto, M.R. Rucco, M. Malardo, C. Ambrosino, B. Squitieri, P. Tassone, and S. Venuta. 1993. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol. 67:2853–2861.
3. Nemerow, G.R., R. Wolfert, M.E. McNaughton, and N.R. Cooper. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor. J. Virol. 55:347-351.
4. Miyamoto, S., and M. Verma. 1995. REL/NF-kappaB story. Adv. Cancer Res. 66:255–292.
5. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705–716.
6. Luxembourg, A.T., and N.R. Cooper. 1994. T cell dependent B cell activating properties of antibody-coated small latex beads: a new model for B cell activation. J. Immuno1. 153:604–614.
7. Nemerow, G.R., and N.R. Cooper. 1981. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J. Immunol. 127:272–278.
8. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer. 33:27–32.
9. Luxembourg, A.T., and N.R. Cooper. 1994. Modulation of signaling via the B cell antigen receptor by C.D21, the receptor for C3dg and Epstein-Barr virus. J. Immunol. 153:4448-4457.
10. Tannen, J., Y. W. Chang, J. Sample, A. Sears, and E. Kieff. 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:4452-4464.
11. Roberts, M.L., A.T. Luxembourg, and N.R. Cooper. 1996. Epstein-Barr virus binding to C.D21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. J. Gen. Virol. 77:3077–3085.
12. Chen, W., and N.R. Cooper. 1996. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. J. Virol. 70:4849–4853.
13. Allard, M.J., D.H. Crawford, and B.E. Griffin. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70:1755–1764.
14. Roney, C., J.G. Howe, S.H. Speck, and G. Miller. 1989. Influences of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3-HR-1 strain of Epstein-Barr virus. J. Virol. 63:1531-1539.
15. Gaerne, G., I. Quinto, M.R. Roccu, M. Malardo, C. Ambrosino, B. Squitieri, P. Tassone, and S. Venuta. 1993. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol. 67:2853–2861.
16. Pale, E., R.I. Scheinman, A.S. Baldwin, and N. Raab-Traub. 1995. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappaB/Rel family proteins. J. Virol. 69:4572–4576.
17. Nemerow, G.R., R. Wolfert, M.E. McNaughton, and N.R. Cooper. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor. J. Virol. 55:347-351.
18. Nemerow, G.R., M.F.E. Siaw, and N.R. Cooper. 1986. Purification of the Epstein-Barr virus C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J. Virol. 58:709–712.
19. Moore, M.D., R.G. DiScipio, N.R. Cooper, and G.R. Nemerow. 1989. Hydrodynamic, electron microscopic and ligand binding analysis of the Epstein-Barr virus C3dg receptor (CR2). J. Biol. Chem. 264:20576–20582.
20. Chen, Z., J. Hagler, V.J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets IkappaB to the ubiquitin-proteasome pathway. Genes Dev. 9:1586–1597.
21. Ghosh, S., and D. Baltimore. 1996. Activation in vitro of NF-kappaB by phosphorylation of its inhibitor IkappaB. Nature (Lond.) 344:678-682.
22. Gopalakrishna, R., Z.H. Chen, and U. Gundimeda. 1992. Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Lett. 314:149–154.
23. Kobayashi, E., H. Nakano, M. Morimoto, and T. Tamaoki. 1989. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:548–553.
24. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science (Wash. DC). 265:956–959.
25. Grilli, M., M. Pizzii, M. Memo, and P. Spano. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science (Wash. DC). 274:1383–1385.
26. Schreck, R., P. Riebeer, and P.A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappaB transcription factor and HIV-1. EMBO J. (Eur. Mol. Biol. Organ.). 10:2247-2258.
27. Sample, J., M. Hummel, D. Braun, M. Birkenbach, and E. Kieff. 1986. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci USA. 83:5096–5100.
28. Sinclair, A.J., and P.J. Farrell. 1995. Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J. Virol. 69:5461–5468.
29. Nemerow, G.R., and N.R. Cooper. 1984. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology. 132:186–198.
30. Grilli, M., J.J.-S. Chiu, and M.J. Lenardo. 1993. NF-kB and Rel: participants in a multiformal transcriptional regulatory system. Int. Rev. Cytol. 143:1–62.
31. Peng, M., and E. Lundgren. 1992. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene. 7:1775–1782.
32. Sinclair, A.J., I. Palmero, G. Peters, and P.J. Farrell. 1994. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO (Eur. Mol. Biol. Organ.) J. 13:3321–3328.
33. Rosen, C.A., J.G. Sodroski, and W.A. Haseltine. 1995. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell. 41:813–823.
34. Hansen, S.K., L. Guerrin, and F. Blasi. 1994. Differential DNA sequence specificity and regulation of HIV-1 enhancer activity by cRel-RelA transcription factor. J. Biol. Chem. 269:22230–22237.
35. Kunsch, C., S.M. Ruben, and C.A. Rosen. 1992. Selection of optimal kB/Rel DNA-binding motifs: interaction of both subunits of NF-kB with DNA is required for transcriptional activation. Mol. Cell Biol. 12:4412–4421.
36. Fujita, T., G.P. Nolan, S. Ghosh, and D. Baltimore. 1992. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kB. Genes Dev. 6:775–787.
37. Beg, A.A., and D. Baltimore. 1996. An essential role for NF-kB in preventing TNF-alpha-induced cell death. Science (Wash. DC). 274:782–783.
38. Wang, C.-Y., M.W. Mayo, and A.S.J. Baldwin. 1996. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science (Wash. DC). 274:784–787.
39. Antwerp, D.J.V., S.J. Martin, T. Kafri, D.R. Green, and I.M. Verma. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kB. Science (Wash. DC). 274:787–789.